Annane, Djillali
Ouanes-Besbes, Lamia
de Backer, Daniel
DU, Bin
Gordon, Anthony C.
Hernández, Glenn
Olsen, Keith M.
Osborn, Tiffany M.
Peake, Sandra
Russell, James A.
Cavazzoni, Sergio Zanotti
Article History
Received: 20 March 2018
Accepted: 22 May 2018
First Online: 4 June 2018
Compliance with ethical standards
:
: DA reports having received a grant from the French Ministry of Health to conduct a trial comparing epinephrine to norepinephrine plus dobutamine for septic shock (CATS). DDB reports that he acts as a consultant to and material for studies by Edwards Lifesciences. ACG reports that outside of this work he has received speaker fees from Orion Corporation Orion Pharma and Amomed Pharma. He has consulted for Ferring Pharmaceuticals, Tenax Therapeutics, Baxter Healthcare, Bristol-Myers Squibb and GSK, and received grant support from Orion Corporation Orion Pharma, Tenax Therapeutics and HCA International with funds paid to his institution. GH reports no financial conflict of interest. JR reports patents owned by the University of British Columbia (UBC) that are related to PCSK9 inhibitor(s) and sepsis and related to the use of vasopressin in septic shock. JR is an inventor on these patents. JR is a founder, Director and shareholder in Cyon Therapeutics Inc. (developing a sepsis therapy (PCSK9 inhibitor)). JR has share options in Leading Biosciences Inc. JR is a shareholder in Molecular You Corp. JR reports receiving consulting fees in the last 3 years from: (1) Asahi Kesai Pharmaceuticals of America (AKPA)(developing recombinant thrombomodulin in sepsis). (2) La Jolla Pharmaceuticals (developing angiotensin II; JR chaired the DSMB of a trial of angiotensin II from 2015 to 2017)—no longer actively consulting. (3) Ferring Pharmaceuticals (manufactures vasopressin and was developing selepressin)—no longer actively consulting. (4) Cubist Pharmaceuticals (now owned by Merck; formerly Trius Pharmaceuticals; developing antibiotics)—no longer 3 actively consulting. (5) Leading Biosciences (was developing a sepsis therapeutic that is no longer in development)—no longer actively consulting. (6) Grifols (sells albumin)—no longer actively consulting. (7) CytoVale Inc. (developing a sepsis diagnostic)—no longer actively consulting. JR reports having received an investigator-initiated grant from Grifols (entitled “Is HBP a mechanism of albumin’s efficacy in human septic shock?”) that is provided to and administered by UBC.
Free to read: This content has been made available to all.